Imugene Ltd has released a press release.
Phase 1 CF33 VAXINIA Study Update - Positive Early Signals
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study
- Imugene Phase 1 onCARlytics CD19 virus clinical trial opens
- Imugene B Cell & OV Platforms Featured at ESMO Congress
- Azer-cel FDA IND Transferred to Imugene
- Imugene Closes SPP Raising $18.2 million
Later from Imugene
- Azer-cel Hits Major Milestone in Phase 1b CAR T Trial
- FDA Fast Track Designation Granted for VAXINIA Trial Program
- Imugene thrilled as VAXINIA granted FDA Fast Track designation
- Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine
- New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene